Online inquiry

IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11398MR)

This product GTTS-WQ11398MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets PDGFRA gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001347829.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5156
UniProt ID P16234
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ11398MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2736MR IVTScrip™ mRNA-Anti-IL23A, AMG-139(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG-139
GTTS-WQ8316MR IVTScrip™ mRNA-Anti-TFRC, HN-66000(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HN-66000
GTTS-WQ9030MR IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMC RON-8
GTTS-WQ14722MR IVTScrip™ mRNA-Anti-SELP, SEG101(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SEG101
GTTS-WQ7363MR IVTScrip™ mRNA-Anti-FZD7, FZD8-Fc(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA FZD8-Fc
GTTS-WQ1910MR IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AGN 150998
GTTS-WQ6679MR IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA DMUC5754A
GTTS-WQ11592MR IVTScrip™ mRNA-Anti-ERBB2, MGAH-22(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MGAH-22
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW